Inside the research
Solventum Corporation
SOLV Research profile · latest available data
Price overview
$89.50
▲ +0.91 (+1.0%)
| 52w hi | $92.44 |
|---|---|
| 52w lo | $62.49 |
| Vol | 578.90K |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.32
| Short | +0.18 |
|---|---|
| Medium | +0.44 |
| Long | +0.40 |
computed 2026-09-27
Key fundamentals
Solventum Corporation
Healthcare · Medical Instruments & Supplies
| Market cap | $15.24B |
|---|---|
| Enterprise value | $20.13B |
| Trailing P/E | 10.94x |
| Forward P/E | 12.38x |
| EV / EBITDA | 17.67x |
| P / S (ttm) | 1.83x |
| Profit margin | 17.3% |
| Return on equity | 34.0% |
| Revenue growth | +2.2% |
| Earnings growth | +3.9% |
| Debt / equity | 110.31 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.27 | |
| Sector | +0.08 | |
| Technical | +0.16 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Risk Metrics
| Beta vs SPX | 0.86 |
|---|---|
| Corr SPX | 0.45 |
| Annual vol | 30.2% |
| Annual ret | +16.9% |
| Sharpe | 0.56 |
| Max DD | -27.5% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $81.08 |
|---|---|
| High / Low | $100.00 / $60.00 |
| Median | $82.00 |
| Analysts | 12 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 4 | |
| Hold | 6 | |
| Sell | 2 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-06 | Wells Fargo | → Equal-Weight |
| 2026-05-06 | UBS | → Neutral |
| 2026-05-06 | Stifel | → Buy |
| 2026-05-06 | Keybanc | → Overweight |
| 2026-05-06 | BTIG | → Buy |
| 2026-04-27 | Keybanc | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-08-05 | Reg FD Disclosure, Other Material Event… | read |
| 2026-07-20 | Officer / Director Change | read |
| 2026-06-05 | Other Material Event, Exhibits | read |
| 2026-05-27 | Officer / Director Change, Exhibits | read |
| 2026-05-20 | Shareholder Vote | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-03-24 | Officer / Director Change, Exhibits | read |
| 2026-02-26 | Earnings Release, Exhibits | read |
| 2025-12-16 | Reg FD Disclosure, Exhibits | read |
| 2025-11-06 | Earnings Release, Exhibits | read |
| 2025-10-21 | Officer / Director Change | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 96.6% |
| HHI | 3,286 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $435.07M | 5.64M |
| Fidelity / FMR LLC | $160.41M | 2.08M |
| Millennium Management | $92.58M | 1.20M |
| AQR Capital Management | $83.48M | 1.08M |
| Capital Research / Capital World | $41.10M | 532.78K |
| Citadel Advisors | $15.06M | 195.23K |
| Bridgewater Associates | $13.73M | 177.92K |
| T. Rowe Price Group | $16.69K | 216.34K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2024–2025 · 2 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $8.32B | +2.4% | |
| Gross profit | $4.69B | +0.0% | |
| Operating income | $1.04B | -38.8% | |
| Net income | $479.00M | -64.4% | |
| Cash from ops | $1.92B | +61.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $88.53 | $89.68 | $88.16 | $89.50 | 578.90K |
| Sep 24 | $88.54 | $89.04 | $88.12 | $88.59 | 635.80K |
| Sep 23 | $88.18 | $89.52 | $87.74 | $88.37 | 860.10K |
| Sep 22 | $89.17 | $89.40 | $88.48 | $88.75 | 651.20K |
| Sep 21 | $88.87 | $89.61 | $88.40 | $88.84 | 660.30K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →